Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Ipsen says FDA extending review date for Reloxin
Chicago - Ipsen says the Food and Drug Administration (FDA) is extending the initial drug review for Reloxin (botulinum toxin type A) to April 13, 2009, Reuters reports.
Chicago
- Ipsen says the Food and Drug Administration (FDA) is extending the initial drug review for Reloxin (botulinum toxin type A) to April 13, 2009, Reuters reports.
Ipsen also says the FDA confirmed the manufacturing process for the product in the Wales facility is in compliance, according to Reuters.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Related Content
